IN2014DN09348A - - Google Patents

Info

Publication number
IN2014DN09348A
IN2014DN09348A IN9348DEN2014A IN2014DN09348A IN 2014DN09348 A IN2014DN09348 A IN 2014DN09348A IN 9348DEN2014 A IN9348DEN2014 A IN 9348DEN2014A IN 2014DN09348 A IN2014DN09348 A IN 2014DN09348A
Authority
IN
India
Prior art keywords
compounds
disorders
substituents
useful
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Matthew C Lucas
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN09348(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2014DN09348A publication Critical patent/IN2014DN09348A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IN9348DEN2014 2012-06-20 2013-06-17 IN2014DN09348A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661961P 2012-06-20 2012-06-20
PCT/EP2013/062461 WO2013189864A1 (en) 2012-06-20 2013-06-17 N-alkyltriazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
IN2014DN09348A true IN2014DN09348A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-17

Family

ID=48628667

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9348DEN2014 IN2014DN09348A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-06-20 2013-06-17

Country Status (22)

Country Link
US (1) US9321738B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2864300A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2015520202A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20150021057A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104411692A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013279512A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014030685A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2869541A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2014003243A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO7131358A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20140525A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA201492285A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1206342A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL236088A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN09348A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA37764A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2014014710A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20142448A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12014502789A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201407220YA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA109868C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013189864A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS
PE20142305A1 (es) * 2012-06-20 2015-01-16 Hoffmann La Roche Compuestos de n-ariltriazol como antagonistas de lpar
AU2014232383B2 (en) 2013-03-15 2019-01-17 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
EP3162801B1 (en) 2014-06-27 2020-07-22 UBE Industries, Ltd. Salt of halogen-substituted heterocyclic compound
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
CN111699180B (zh) 2017-12-19 2024-11-29 百时美施贵宝公司 作为lpa拮抗剂的吡唑n-连接的氨基甲酰基环己基酸
TW201927778A (zh) * 2017-12-19 2019-07-16 美商必治妥美雅史谷比公司 作為lpa拮抗劑之環己基酸三唑唑類
CN112041029B (zh) 2017-12-19 2025-01-24 百时美施贵宝公司 作为lpa拮抗剂的环己基酸吡唑唑类
ES2936517T3 (es) * 2017-12-19 2023-03-17 Bristol Myers Squibb Co Triazol azinas de ácido ciclohexílico como antagonistas de LPA
CN111479807B (zh) * 2017-12-19 2024-11-26 百时美施贵宝公司 作为lpa拮抗剂的环己基酸异噁唑吖嗪
KR102756639B1 (ko) * 2017-12-19 2025-01-16 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 이속사졸 아졸
EP3728222B1 (en) * 2017-12-19 2023-03-29 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as lpa antagonists
EP3728210A1 (en) 2017-12-19 2020-10-28 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
JP7369125B2 (ja) * 2017-12-19 2023-10-25 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのイソキサゾールo-架橋カルバモイルシクロヘキシル酸
JP7202383B2 (ja) 2017-12-19 2023-01-11 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのピラゾールo-架橋カルバモイルシクロヘキシル酸
WO2019126090A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
AU2018395275A1 (en) * 2017-12-29 2020-07-16 Biomarin Pharmaceutical Inc. Glycolate oxidase inhibitors for the treatment of disease
KR20210061383A (ko) * 2018-09-18 2021-05-27 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로펜틸 산
WO2020060914A1 (en) * 2018-09-18 2020-03-26 Bristol-Myers Squibb Company Oxabicyclo acids as lpa antagonists
WO2020060916A1 (en) * 2018-09-18 2020-03-26 Bristol-Myers Squibb Company Cycloheptyl acids as lpa antagonists
CN114728168B (zh) * 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
TWI853704B (zh) 2021-05-11 2024-08-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
AU2022273702B2 (en) * 2021-05-13 2025-05-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
AR128613A1 (es) 2022-02-25 2024-05-29 Lhotse Bio Inc Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
US9272990B2 (en) * 2010-12-07 2016-03-01 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
WO2012138648A1 (en) 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
EP2744807A4 (en) 2011-08-15 2015-03-04 Intermune Inc COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
CL2014003243A1 (es) 2015-03-20
EA201492285A1 (ru) 2015-04-30
SG11201407220YA (en) 2014-12-30
EP2864300A1 (en) 2015-04-29
US20150133511A1 (en) 2015-05-14
UA109868C2 (ru) 2015-10-12
PH12014502789A1 (en) 2015-02-09
MA37764A1 (fr) 2016-01-29
CA2869541A1 (en) 2013-12-27
WO2013189864A1 (en) 2013-12-27
BR112014030685A2 (pt) 2017-06-27
AU2013279512A1 (en) 2014-10-16
JP2015520202A (ja) 2015-07-16
HK1206342A1 (en) 2016-01-08
MX2014014710A (es) 2015-03-04
CN104411692A (zh) 2015-03-11
PE20142448A1 (es) 2015-01-28
KR20150021057A (ko) 2015-02-27
US9321738B2 (en) 2016-04-26
IL236088A0 (en) 2015-02-01
CO7131358A2 (es) 2014-12-01
CR20140525A (es) 2015-01-12

Similar Documents

Publication Publication Date Title
IN2014DN09352A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN2014DN09348A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN2014DN09347A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN2014MN02598A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH12016500024A1 (en) Bromodomain inhibitor
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
IN2015DN01119A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN2014DN09434A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
PH12014501542A1 (en) Substituted pyrrolidine -2- carboxamides
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
MX2016002794A (es) Compuestos antiproliferativos.
IN2014DN06869A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX340574B (es) Imidazo pirazinas.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2015001657A (es) Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
IN2013DN02555A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
WO2015002755A3 (en) Compounds for the treatment of malaria
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders